{"id":"NCT01962922","sponsor":"Veloxis Pharmaceuticals","briefTitle":"Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.","officialTitle":"Prospective, Rand, Open-label, Single-center, 2 Sequence, 3 Period Crossover Study to Compare the Steady State PK of Once-Daily-Extended Release LCP-Tacro to Generic Tacrolimus Capsules Twice Daily in Stable A A Renal Transplant pt.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11","primaryCompletion":"2015-07","completion":"2015-08","firstPosted":"2013-10-14","resultsPosted":"2016-08-15","lastUpdate":"2018-06-06"},"enrollment":50,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Renal Failure"],"interventions":[{"type":"DRUG","name":"LCP-Tacro","otherNames":["Envarsus XR"]},{"type":"DRUG","name":"Tacrolimus -IR","otherNames":["Prograf","Generic Tacrolimus"]}],"arms":[{"label":"LCP-Tacro","type":"ACTIVE_COMPARATOR"},{"label":"Tacrolimus - IR","type":"ACTIVE_COMPARATOR"}],"summary":"Open label, prospective, single-center, randomized, two sequence, three period crossover study to compare the steady state pharmacokinetics of LCP-Tacro tables to generic tacrolimus capsules administered twice daily in stable African-American renal transplant patients.","primaryOutcome":{"measure":"Evaluation of AUC(0-24) for Envarsus XR and IR-Tac","timeFrame":"Day 7","effectByArm":[{"arm":"Envarsus XR","deltaMin":251.9,"sd":77.78},{"arm":"Tacrolimus - IR","deltaMin":247.9,"sd":102.33}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":19},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":["29162334"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":50},"commonTop":["Blood creatinine increased","Nasopharyngitis","Headache","Diarrhoea","Nausea"]}}